SCHEMBL9852104

SCHEMBL9852104

Nc1nc(-c2ccco2)ns1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.53
HSD17B10 Q99714 4/20 0.53
ADORA2A P29274 6/20 0.52
ADORA1 P30542 6/20 0.52
ADORA3 P0DMS8 4/20 0.52
ADORA2B P29275 3/20 0.52
POLB P06746 3/20 0.50
APAF1 O14727 1/20 0.50
NPC1 O15118 1/20 0.50
NSD2 O96028 1/20 0.50
RAB9A P51151 1/20 0.50
CACNA1B Q00975 1/20 0.50
APBA1 Q02410 1/20 0.50
SAE1 Q9UBE0 1/20 0.50
UBA2 Q9UBT2 1/20 0.50
ALDH1A1 P00352 5/20 0.49
BLM P54132 3/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
PKM P14618 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8810396 0.79 POLB (0.52) MAPTHSD17B10ADORA2AADORA1ADORA3
SCHEMBL6529837 0.78 POLB (0.50) MAPTHSD17B10ADORA2AADORA1ADORA3
SCHEMBL8494359 0.72 ALDH1A1 (0.63) MAPTHSD17B10ADORA2AADORA1ADORA3
SCHEMBL10723578 0.72 ALDH1A1 (0.63) MAPTHSD17B10ADORA2AADORA1ADORA3
SCHEMBL9091999 0.71 ALDH1A1 (0.45) MAPTHSD17B10ADORA2AADORA1ADORA3
SCHEMBL15364087 0.70 CASP3 (0.52) MAPTHSD17B10ADORA2AADORA1ADORA3
SCHEMBL6003356 0.70 ADORA3 (0.58) ADORA2AADORA1ADORA3ADORA2BNPC1
SCHEMBL653613 0.69 MAPT (1.00) MAPTHSD17B10ADORA2AADORA1POLB
SCHEMBL69810 0.68 ADORA3 (1.00) MAPTADORA2AADORA1ADORA3ADORA2B
SCHEMBL13528571 0.68 NPC1 (1.00) MAPTHSD17B10ADORA2AADORA1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334948-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV NOVALIX DEUTSCHLAND GMBH (DE) 2017-11-23 US disclosed
US-9745339-B2 Ligands for antibody and Fc-fusion protein purification by affinity chromotography IV NOVALIX DEUTSCHLAND GMBH (DE) 2017-08-29 US disclosed
US-20160009760-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV GRAFFINITY PHARMACEUTICALS GMBH (DE) 2016-01-14 US disclosed
EP-2812346-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV Graffinity Pharmaceuticals GmbH (DE) 2014-12-17 EP disclosed
WO-2013117707-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV GRAFFINITY PHARMACEUTICALS GMBH (DE) 2013-08-15 WO disclosed
EP-0455356-A1 Substituted 5-amino-1,2,4-thiadiazoles with pharmaceutical activity LILLY INDUSTRIES LIMITED (GB) 1991-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334948-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV FCGR1A, FCGR2A, FCGR3B MAPT 3952/4885HSD17B10 4170/4885ADORA2A 1234/4885
US-20160009760-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV FCGR1A, FCGR2A, FCGR3B MAPT 3892/4885HSD17B10 4166/4885ADORA2A 1444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.